P020 | EXTENDED LEAD-IN PHASE OF BRENTUXIMAB VEDOTIN AND SHORTENED AVD IN OLDER PATIENTS (>60 YEARS) WITH ADVANCED HODGKIN LYMPHOMA (HL) AND HIGH COMORBIDITY BURDEN (ECOG≥2 AND/OR CIRS-G>10).

Introduction: Older patients (pts) with Hodgkin Lymphoma (HL) have worse outcomes due to biological characteristics, poor performance status (PS), and comorbidities. Standard treatment may not suit many pts due to reduced tolerance, including high Doxorubicin load. We investigated whether Brentuxim...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autori principali:	M. Bonanni, A. Cuccaro , S. Mele , E. Morelli, A. Fresa, M. Arcamone, F. Ibello, M. Esposito, M. Saggese, S. Crisci, M. Rivieccio, L. Simeone, F. Volzone, G. Corazzelli, R. De Filippi, A. Pinto
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Ferrata Storti Foundation 2025-09-01
Serie:	Haematologica
Accesso online:	https://haematologica.org/article/view/12517
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

P020 | EXTENDED LEAD-IN PHASE OF BRENTUXIMAB VEDOTIN AND SHORTENED AVD IN OLDER PATIENTS (&gt;60 YEARS) WITH ADVANCED HODGKIN LYMPHOMA (HL) AND HIGH COMORBIDITY BURDEN (ECOG≥2 AND/OR CIRS-G&gt;10).

Documenti analoghi

P020 | EXTENDED LEAD-IN PHASE OF BRENTUXIMAB VEDOTIN AND SHORTENED AVD IN OLDER PATIENTS (>60 YEARS) WITH ADVANCED HODGKIN LYMPHOMA (HL) AND HIGH COMORBIDITY BURDEN (ECOG≥2 AND/OR CIRS-G>10).